SPARQL
Downloads
Documentation/Help
Skip Header
Results
Your Query
Add common prefixes
DESCRIBE <http://purl.uniprot.org/SHA-384/B9399946810928C7573BD1C01502F987233F71BE2098B52A053805C442F041D97F18DB972C86C3A356840C0A6E82BFC3>
Submit Query
Cancel
RDF/XML
NTriples
Turtle
Show query
Share
Subject
Predicate
Object
http://purl.uniprot.org/SHA-384/B9399946810928C7573BD1C01502F987233F71BE2098B52A053805C442F041D97F18DB972C86C3A356840C0A6E82BFC3
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://purl.uniprot.org/core/Annotation
http://purl.uniprot.org/SHA-384/B9399946810928C7573BD1C01502F987233F71BE2098B52A053805C442F041D97F18DB972C86C3A356840C0A6E82BFC3
http://www.w3.org/2000/01/rdf-schema#comment
"Data indicate a potent and specific ADAM metallopeptidase domain 17 (ADAM17) inhibitory antibody MEDI3622 which induces tumor regression or stasis in many epidermal growth factor receptor (EGFR)-dependent tumor models."
xsd:string
http://purl.uniprot.org/uniprot/#_6536E184011A89E2D0A47D526104EDDAD83723279B7F4B77A76F1E22AB0F5209900E3CF639B3CD47833C02FCEF65B9B2
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
http://purl.uniprot.org/SHA-384/B9399946810928C7573BD1C01502F987233F71BE2098B52A053805C442F041D97F18DB972C86C3A356840C0A6E82BFC3
http://purl.uniprot.org/uniprot/C9JYS6
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/B9399946810928C7573BD1C01502F987233F71BE2098B52A053805C442F041D97F18DB972C86C3A356840C0A6E82BFC3
http://purl.uniprot.org/uniprot/#_C9JYS6-mappedCitation-25948294
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/B9399946810928C7573BD1C01502F987233F71BE2098B52A053805C442F041D97F18DB972C86C3A356840C0A6E82BFC3